Skip to main content
. Author manuscript; available in PMC: 2016 Sep 10.
Published in final edited form as: Cell Rep. 2015 Mar 12;10(10):1778–1791. doi: 10.1016/j.celrep.2015.02.033

Figure 4. SUMOylated JARID1B and PML are rapidly degraded by the proteasome upon MMS treatment.

Figure 4

U2OS cells stably expressing His10-tagged SUMO-2 were treated with 0.02% MMS for the indicated amount of time. One set of cells was additionally treated with the proteasome inhibitor MG132 at 10 μM. Cells were lysed, and His10-pulldown was performed to enrich SUMOylated proteins. Total lysates and SUMO-enriched fractions were analyzed by immunoblotting using antibodies against JARID1B and PML. Ponceau-S staining was performed on total lysate fractions as a loading control.